Related Experiment Video
Updated: Jul 2, 2026
07:41
Behavioral Assessment of Visual Function via Optomotor Response and Cognitive Function via Y-Maze in Diabetic Rats
Published on: October 23, 2020
The ChromaTest, a digital color contrast sensitivity analyzer, for diabetic maculopathy: a pilot study
Roger Wong1, Jaheed Khan, Temi Adewoyin
1Ophthalmology Department, Retinal Research Unit, King's College Hospital NHS Trust, Denmark Hill, London, UK. drrogerwong@gmail.com
BMC Ophthalmology
|August 19, 2008
Summary
The Chromatest shows changes in tritan color vision in diabetic retinopathy patients. However, it is not yet suitable for screening diabetic maculopathy.
Area of Science:
- Ophthalmology
- Medical Diagnostics
- Vision Science
Background:
- Diabetic maculopathy is a significant complication of diabetes.
- Early detection of diabetic maculopathy is crucial for preventing vision loss.
Purpose of the Study:
- To evaluate the effectiveness of the Chromatest in assessing diabetic maculopathy.
- To investigate color contrast sensitivity changes in patients with diabetic retinopathy.
Main Methods:
- 150 patients with Type 2 diabetes were recruited.
- Visual acuity and color contrast sensitivity using Chromatest were assessed.
- Dilated fundoscopy confirmed diabetic retinopathy stage.
Main Results:
- Significant differences in protan and tritan color contrast thresholds were observed between eyes with clinically significant macular edema (CSMO) and non-proliferative diabetic retinopathy (NPDR).
- The Chromatest achieved 71% sensitivity and 70% specificity for screening CSMO.
- Threshold levels were derived from the same dataset, limiting definitive conclusions on screening effectiveness.
Conclusions:
- The Chromatest is a user-friendly tool for assessing color contrast sensitivity.
- While not yet validated for screening diabetic maculopathy, the study confirmed tritan color vision deficits in diabetic retinopathy.
